Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Glycomine raises $12 million

by Lisa M. Jarvis
November 21, 2016 | A version of this story appeared in Volume 94, Issue 46

Rare disease-focused Glycomine has raised $12 million in its first major round of financing, with support from Sanderling Ventures, Chiesi Ventures, high-net-worth individuals, and patients. Glycomine is developing substrate replacement therapies for two rare genetic diseases—congenital disorder of glycosylation Type Ia (CDG-Ia) and N-glycanase deficiency (Ngly1)—that currently lack treatments. The roughly 1,000 people with CDG-Ia are deficient in phosphomannomutase 2, an enzyme needed to produce glycoproteins.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.